Eltrombopag Olamine – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 55 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Eltrombopag Olamine - Uses, Dosage, Side Effects, Interaction
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Eltrombopag is an orally active thrombopoietin receptor agonist with megakaryopoiesis-stimulating activity. Eltrombopag binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietic receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of megakaryocytes, thereby increasing the production...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Eltrombopag is an orally active thrombopoietin receptor agonist with megakaryopoiesis-stimulating activity. Eltrombopag binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietic receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of megakaryocytes, thereby increasing the production of blood platelets. Eltrombopag is a hydrazine in which each nitrogen atom is substituted, one by a 3'-carboxy-2-hydroxy[1,1'-biphenyl]-3-yl group and the other by...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Eltrombopag is an orally active thrombopoietin receptor agonist with megakaryopoiesis-stimulating activity. Eltrombopag binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietic receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of megakaryocytes, thereby increasing the production of blood platelets.

Eltrombopag is a hydrazine in which each nitrogen atom is substituted, one by a 3′-carboxy-2-hydroxy[1,1′-biphenyl]-3-yl group and the other by a 1-(3,4-dimethyl phenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazole-4-ylidene group. A small molecule agonist of the c-mpl (TpoR) receptor (the physiological target of the hormone thrombopoietin), it has been developed as a medication for conditions that lead to platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia (abnormally low platelet counts). It has a role as a thrombopoietin receptor agonist and a xenobiotic. It is a member of hydrazines, a member of pyrazoles, and a member of benzoic acids.

Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.

Eltrombopag Olamine is the orally active ethanolamine salt of eltrombopag, a small-molecule, nonpeptide thrombopoietin receptor agonist with megakaryopoiesis-stimulating activity. Eltrombopag binds to and stimulates the transmembrane domain of the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietic receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of cells in the megakaryocytic lineage and an increase in platelet production.

Mechanism of Action

Eltrombopag is an orally bioavailable, small-molecule TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor. Eltrombopag is a stimulator of STAT and JAK phosphorylation. Unlike recombinant TPO or romiplostim, Eltrombopag does not activate the AKT pathway in any way. It should be noted that when given to patients with aplastic anemia, other lineages besides platelet count were increased, suggesting that either eltrombopag enhanced the effect of TPO in vivo; or there is a yet uncovered mechanism of action at work.

Eltrombopag is an orally bioavailable, small-molecule thrombopoietin (TPO)-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor and initiates signaling cascades that induce proliferation and differentiation from bone marrow progenitor cells.

Indications

  • Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction.
  • Eltrombopag is indicated for the treatment of adult patients with primary immune platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia (ITP) who are refractory to other treatments (e. g. corticosteroids, and immunoglobulins).
  • Eltrombopagis indicated for the treatment of pediatric patients aged 1 year and above with primary immune platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. g. corticosteroids, immunoglobulins).
  • Eltrombopag is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.
  • Eltrombopag is indicated in adult patients with acquired severe aplastic anemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for hematopoietic stem cell transplantation
  • Eltrombopag is indicated for the treatment of platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
  • Eltrombopag is indicated for the treatment of platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy.
  • Eltrombopag is indicated for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.
  • Eltrombopag should be used only in patients with immune (idiopathic) platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia (ITP) whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Promacta should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for the treatment of chronic hepatitis C infection.
  •  In combination with standard immunosuppressive therapy as first-line treatment of patients with severe aplastic anemia.

Use in Cancer.

Eltrombopag olamine is approved to treat:

  • Thrombocytopenia (low platelet levels). It is used in adults and in children aged 1 year or older with chronic immune thrombocytopenia (ITP). ITP is a condition in which platelets are destroyed by the immune system. Eltrombopag olamine is used in certain patients with ITP who have not gotten better with other treatments.

Eltrombopag olamine is also being studied in the treatment of other conditions and types of cancer.

Contraindications

  • increase in the number of platelets in the blood
  • clouding of the lens of the eye called cataracts
  • obstruction of a blood vessel by a blood clot
  • a blood clot in a vein of the liver
  • at risk for formation of blood clots
  • acute liver failure
  • damage to the liver and inflammation
  • decreased kidney function
  • high amount of bilirubin in the blood
  • abnormal liver function tests
  • a patient who is producing milk and breastfeeding
  • antiphospholipid antibody syndrome
  • abnormal blood clotting due to factor V leiden mutation
  • hereditary antithrombin III deficiency
  • Child-Pugh class A liver impairment
  • Child-Pugh class B liver impairment
  • Child-Pugh class C liver impairment

Dosage

Strengths: 25 mg; 50 mg; 75 mg; 12.5 mg

Aplastic Anemia

FIRST-LINE SEVERE APLASTIC ANEMIA:

  • Initial dose: 150 mg orally once a day

Patients of Asian Ancestry (such as Chinese, Japanese, Taiwanese, Korean, or Thai):

  • Initial dose: 75 mg orally once a day
  • Duration of therapy: 6 months
  • If baseline ALT or AST levels are greater than 6 times the upper limit of normal (ULN), do not initiate this drug until transaminase levels are less than 5 x ULN.
  • Initiate this drug concurrently with standard immunosuppressive therapy.
  • Do not exceed the initial dose.

REFRACTORY SEVERE APLASTIC ANEMIA:

  • Initial dose: 50 mg orally once a day; may adjust the dose in 50 mg increments every 2 weeks as needed to achieve a platelet count between 50 and 200 x 10(9)/L.
  • Initial dose: 25 mg orally once a day; may adjust the dose in 50 mg increments every 2 weeks as needed to achieve a platelet count between 50 and 200 x 10(9)/L.
  • Maintenance dose: The lowest dose needed to achieve and maintain a platelet count between 50 and 200 x 10(9)/L.
  • Maximum dose: 150 mg orally once a day
  • Duration of therapy: If no hematologic response has occurred after 16 weeks of therapy with this drug, discontinue therapy.
  • For patients who achieve trilineage response, including transfusion independence, lasting at least 8 weeks, the dose of this drug may be reduced by 50%. If counts remain stable after 8 weeks at the reduced dose, then this drug may be discontinued. If platelet counts drop to less than 30 x 10(9)/L, hemoglobin to less than 9 g/dL, or absolute neutrophil count (ANC) to less than 0.5 x 10(9)/L, this drug may be reinitiated at the previous effective dose
  • If new cytogenetic abnormalities are observed, consider discontinuation of this drug.

Idiopathic (Immune) Thrombocytopenic Purpura

  • Initial dose: 50 mg orally once a day
  • Initial dose: 25 mg orally once a day
  • Maintenance dose: The lowest dose to achieve and maintain a platelet count between 50 to 200 x 10(9)/L as necessary to reduce the risk of bleeding.
  • Maximum dose: 75 mg orally once a day
  • Duration: Treatment should be discontinued if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks of therapy at the maximum daily dose.
  • Monitor CBC with differentials, including platelet counts, every week until the platelet count is stable, followed by monthly thereafter. Monitoring should continue every week for at least 4 weeks following treatment discontinuation.
  • Platelet counts generally increase within 1 to 2 weeks after starting therapy and decrease within 1 to 2 weeks after treatment discontinuation.

Thrombocytopenia

  • Initial dose: 25 mg orally once a day
  • Maintenance dose: The lowest dose to achieve and maintain a platelet count necessary to initiate and maintain antiviral therapy with pegylated interferon and ribavirin.
  • Maximum dose: 100 mg orally once a day
  • Duration: Treatment should be discontinued when concomitant antiviral therapy is discontinued
  • Adjust the daily dose by increments of 25 mg every two weeks as necessary according to platelet count response.
  • Monitor platelet counts every week prior to starting antiviral therapy.
  • During antiviral therapy, monitor CBC with differentials, including platelet counts, every week until the platelet count is stable. Monitor platelet counts monthly thereafter.
  • Platelet counts generally begin to rise within the first week of treatment with eltrombopag.
  • Treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy.

Pediatric Dose

Idiopathic (Immune) Thrombocytopenic Purpura

1 TO 5 YEARS:

  • Initial dose: 25 mg orally once a day

6 YEARS OR OLDER:

  • Initial dose: 50 mg orally once a day
  • Initial dose: 25 mg orally once a day
  • Maintenance dose: The lowest dose to achieve and maintain a platelet count between 50 to 200 x 10(9)/L as necessary to reduce the risk of bleeding.
  • Maximum dose: 75 mg orally once a day
  • Duration: Treatment should be discontinued if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks of therapy at the maximum daily dose.
  • Monitor CBC with differentials, including platelet counts, every week until the platelet count is stable, followed by monthly thereafter. Monitoring should continue every week for at least 4 weeks following treatment discontinuation.
  • Platelet counts generally increase within 1 to 2 weeks after starting therapy and decrease within 1 to 2 weeks after treatment discontinuation.

Aplastic Anemia

FIRST-LINE SEVERE APLASTIC ANEMIA:
Initial dose:

  • 2 to 5 years: 2.5 mg/kg orally once a day
  • 6 to 11 years: 75 mg orally once a day
  • 12 years or older: 150 mg orally once a day

Patients of Asian ancestry (such as Chinese, Japanese, Taiwanese, Korean, or Thai):
Initial dose:

  • 2 to 5 years: 1.25 mg/kg orally once a day
  • 6 to 11 years: 37.5 mg orally once a day
  • 12 years or older: 75 mg orally once a day
  • Duration of therapy: 6 months
  • If baseline ALT or AST levels are greater than 6 times the upper limit of normal (ULN), do not initiate this drug until transaminase levels are less than 5 x ULN.
  • Initiate this drug concurrently with standard immunosuppressive therapy.
  • Do not exceed the initial dose.

Liver Dose Adjustments

CHRONIC IMMUNE THROMBOCYTOPENIA:

  • Mild to severe liver dysfunction (Child-Pugh A, B, or C): Initiate dose at 25 mg orally once a day
  • Mild to severe liver dysfunction with East Asian ancestry: Initiate dose at 12.5 mg orally once a day
  • In patients with liver dysfunction (Child-Pugh Class A, B, C), after initiating eltrombopag or after any subsequent dosing increase, wait 3 weeks before increasing the dose.

CHRONIC HEPATITIS C-ASSOCIATED THROMBOCYTOPENIA:

  • Liver dysfunction: No dosage adjustment is recommended

FIRST-LINE SEVERE APLASTIC ANEMIA:

  • If baseline ALT or AST levels are greater than 6 times the upper limit of normal (ULN), do not initiate this drug until transaminase levels are less than 5 x ULN.

Mild to Severe Liver Dysfunction (Child-Pugh A, B, or C):
Initial dose:

  • 2 to 5 years: 1.25 mg/kg orally once a day for 6 months
  • 6 to 11 years: 37.5 mg orally once a day for 6 months
  • 12 years or older: 75 mg orally once a day for 6 months
  • Increase in ALT or AST greater than 6 x ULN: Discontinue this drug. Once ALT or AST is less than 5 x ULN, reinitiate this drug at the same dose.
  • Increase in ALT or AST greater than 6 x ULN after reinitiating this drug: Discontinue this drug and monitor ALT or AST at least every 3 to 4 days. Once ALT or AST is less than 5 x ULN, reinitiate this drug at a daily dose reduced by 25 mg compared to the previous dose.
  • If ALT or AST returns to greater than 6 x ULN on the reduced dose: Reduce the daily dose of this drug by 25 mg until ALT or AST is less than 5 x ULN. In pediatric patients, less than 12 years of age, reduce the daily dose by at least 15% to the nearest dose that can be administered.

REFRACTORY SEVERE APLASTIC ANEMIA:
Mild to Severe Liver Dysfunction (Child-Pugh A, B, or C):

  • Initial dose: 25 mg orally once a day

GENERAL:
Discontinue eltrombopag if ALT levels increase by at least 3 x ULN in patients with normal liver function or transaminases increase by at least 3 x baseline levels in patients with elevated transaminases pretreatment and where transaminases are:

  • Progressively increasing,
  • Persistent for at least 4 weeks,
  • Accompanied by increased direct bilirubin, or
  • Accompanied by clinical symptoms of liver injury or evidence of hepatic decompensation
  • Treatment may be cautiously restarted if the benefits outweigh the risks, with weekly LFT monitoring during the dose adjustment phase; however, it should be permanently discontinued if LFT abnormalities remain, worsen, or reoccur.

Dose Adjustments

General:

  • A period of at least 2 weeks is recommended between dose adjustments in order to see the effect on the platelet count.
  • Excessive platelet count responses necessitate eltrombopag treatment discontinuation.

Thrombocytopenia in Patients with Chronic ITP:

  • General: Modify the dosage regimen of concomitant ITP medications, as medically appropriate, to avoid
    excessive increases in platelet counts during eltrombopag therapy.

Platelet count:

  • Less than 50 x 10(9)/L following at least 2 weeks of eltrombopag therapy: Increase daily dose by 25 mg to a maximum of 75 mg per day. For patients taking 12.5 mg once a day, increase the dose to 25 mg once a day before increasing the dose amount by 25 mg.
  • Greater than or equal to 200 x 10(9)/L to less than or equal to 400 x 10(9)/L at any time: Decrease the daily dose by 25 mg. For patients taking 25 mg once a day, decrease the dose to 12.5 mg once a day.
  • Greater than 400 x 10(9)/L: Stop eltrombopag; increase platelet monitoring to twice weekly. Once the platelet count is less than 150 x 10(9)/L, restart eltrombopag at a daily dose reduced by 25 mg. For patients taking 25 mg once a day, restart therapy at 12.5 mg once a day.
  • Greater than 400 x 10(9)/L after 2 weeks of therapy at the lowest dose of eltrombopag: Discontinue eltrombopag

Thrombocytopenia in Patients with Chronic Hepatitis C:
General:

  • During antiviral therapy, the dose of eltrombopag should be adjusted to avoid dose reductions of peginterferon.
  • Eltrombopag should be discontinued when antiviral therapy is discontinued.

Platelet count:

  • Less than 50 x 10(9)/L following at least 2 weeks of eltrombopag therapy: Increase daily dose by 25 mg to a maximum of 100 mg per day
  • Greater than or equal to 200 x 10(9)/L to less than or equal to 400 x 10(9)/L at any time: Decrease the daily dose by 25 mg
  • Greater than 400 x 10(9)/L: Stop eltrombopag; increase platelet monitoring to twice weekly. Once the platelet count is less than 150 x 10(9)/L, restart eltrombopag at a daily dose reduced by 25 mg. For patients taking 25 mg once a day, restart therapy at 12.5 mg once a day.
  • Greater than 400 x 10(9)/L after 2 weeks of therapy at the lowest dose of eltrombopag: Discontinue eltrombopag

First-line Severe Aplastic Anemia:
Platelet count:

  • Greater than 200 x 10(9)/L to less than or equal to 400 x 10(9)/L: Decrease the daily dose by 25 mg every 2 weeks to the lowest dose that maintains a platelet count of at least 50 x 10(9)/L. In pediatric patients less than 12 years of age, decrease the dose by 12.5 mg.
  • Greater than 400 x 10(9)/L: Discontinue this drug for 1 week. Once the platelet count is less than 200 x 10(9)/L, reinitiate this drug at a daily dose reduced by 25 mg (or 12.5 mg in pediatric patients less than 12 years of age).

Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolus, stroke, myocardial infarction): Discontinue this drug but remain on horse anti-thymocyte globulin (h-ATG) and cyclosporine.

Refractory Severe Aplastic Anemia:

Platelet count:

  • Less than 50 x 10(9)/L following at least 2 weeks of this drug: Increase daily dose by 50 mg to a maximum of 150 mg/day. For patients taking 25 mg once a day, increase the dose to 50 mg once a day before increasing the dose amount by 50 mg.
  • Greater than or equal to 200 x 10(9)/L to less than or equal to 400 x 10(9)/L at any time: Decrease the daily dose by 50 mg.
  • Greater than 400 x 10(9)/L: Stop this drug for 1 week. Once the platelet count is less than 150 x 10(9)/L, reinitiate therapy at a dose reduced by 50 mg.
  • Greater than 400 x 10(9)/L after 2 weeks of therapy at the lowest dose of this drug: Discontinue this drug.

Administration advice:

  • This drug should be taken without a meal or with a meal low in calcium (50 mg or less) and at least 2 hours before or 4 hours after other medications (e.g., antacids), calcium-rich foods, or supplements containing polyvalent cations such as iron, calcium, aluminum, magnesium, selenium, and zinc.
  • Do not administer more than one dose of eltrombopag within any 24-hour period.
  • Do not split, chew, or crush tablets and mix them with food or liquids.

Side Effects

The Most Common

  • back pain
  • muscle aches or spasms
  • headache
  • flu symptoms such as fever, headache, sore throat, cough, tiredness, chills, and body aches
  • weakness
  • extreme tiredness
  • decreased appetite
  • pain or swelling in the mouth or throat
  • hair loss
  • rash
  • skin color changes
  • skin tingling, itching, or burning
  • swelling of the ankles, feet, or lower legs
  • toothache (in children)
  • swelling, pain, tenderness, warmth or redness in one leg
  • shortness of breath, coughing up blood, fast heartbeat, fast breathing, pain when breathing deeply
  • pain in the chest, arms, back, neck, jaw, or stomach, breaking out in cold sweat, lightheadedness
  • slow or difficult speech, sudden weakness or numbness of the face, arm or leg, sudden headache, sudden vision problems, sudden difficulty walking
  • stomach pain, nausea, vomiting, diarrhea
  • cloudy, blurry vision, or other vision changes

More common

  • Bloating or swelling of the face, arms, hands, lower legs, or feet
  • body aches or pain
  • chills
  • cough
  • difficulty with breathing
  • fever
  • headache
  • loss of voice
  • pain in the chest, groin, or legs, especially the calves
  • pale skin
  • rapid weight gain
  • runny nose
  • severe, sudden headache
  • slurred speech
  • sore throat
  • sudden loss of coordination
  • sudden, severe weakness or numbness in the arm or leg
  • tingling of the hands or feet
  • troubled breathing with exertion
  • unusual tiredness or weakness
  • unusual weight gain or loss
  • yellow eyes or skin
  • Decreased appetite
  • difficulty with moving
  • hair loss or thinning of the hair
  • itching skin
  • lack or loss of strength
  • muscle cramps or stiffness
  • swollen joints

Rare

  • Bladder pain
  • blindness
  • blurred or decreased vision
  • bruising
  • burning, crawling, itching, numbness, prickling, “pins and needles”, or tingling feelings
  • diarrhea
  • a general feeling of discomfort or illness
  • hoarseness
  • joint pain
  • lower back or side pain
  • muscle aches and pains
  • nausea
  • pinpoint red spots on the skin
  • redness of the eye
  • shivering
  • sweating
  • tender, swollen glands in the neck
  • trouble sleeping
  • trouble swallowing
  • voice changes
  • vomiting
  • Back pain
  • belching
  • bone pain
  • darkening of the skin
  • dry mouth
  • heartburn
  • indigestion
  • rash
  • stomach discomfort, upset, or pain

Drug Interactions

Pregnancy and Lactation

FDA Pregnancy Category C

Pregnancy

There are no adequate and well-controlled studies of eltrombopag use in pregnancy. In animal reproduction and developmental toxicity studies, there was evidence of embryolethality and reduced fetal weights at maternally toxic doses. PROMACTA should be us

Lactation

It is not known whether eltrombopag is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from PROMACTA, a decision should be made whether to discontinue nursing or to
discontinue PROMACTA taking into account the importance of PROMACTA to the mother and the known benefits of nursing.

How should this medicine be used?

Eltrombopag comes as a tablet and as a powder for oral suspension (liquid) to take by mouth. It is usually taken once a day on an empty stomach, at least 1 hour before or 2 hours after eating. Take eltrombopag at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take eltrombopag exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Take eltrombopag at least 2 hours before or 4 hours after you eat or drink foods that contain a lot of calcium, such as dairy products, calcium-fortified juices, cereals, oatmeal, and bread; trout; clams; leafy green vegetables such as spinach and collard greens; and tofu and other soy products. Ask your doctor if you are not sure if a food contains a lot of calcium. You may find it helpful to take eltrombopag close to the beginning or end of your day so that you will be able to eat these foods during most of your waking hours.

Swallow the tablets whole. Do not split, chew, or crush them and mix them into food or liquids.

If you are taking the powder for oral suspension, carefully read the manufacturer’s instructions for use that comes with the medication. These instructions describe how to prepare and measure your dose. Mix the powder with cool or cold water before use. Do not mix the powder with hot water. Immediately after preparation, swallow the dose. If it is not taken within 30 minutes or if there is remaining liquid, dispose of the mixture in the trash (do not pour it down the sink).

Do not allow the powder to touch your skin. If you spill the powder on your skin, wash it off immediately with soap and water. Call your doctor if you have a skin reaction or if you have any questions.

Your doctor will probably start you on a low dose of eltrombopag and adjust your dose depending on your response to the medication. At the beginning of your treatment, your doctor will order a blood test to check your platelet level once every week. Your doctor may increase your dose if your platelet level is too low. If your platelet level is too high, your doctor may decrease your dose or may not give you eltrombopag for a time. After your treatment has continued for some time and your doctor has found the dose of eltrombopag that works for you, your platelet level will be checked less often. Your platelet level will also be checked weekly for at least 4 weeks after you stop taking eltrombopag.

If you have chronic ITP, you may receive other medications to treat your condition along with eltrombopag. Your doctor may decrease your dose of these medications if eltrombopag works well for you.

Eltrombopag does not work for everyone. If your platelet level does not increase enough after you have taken eltrombopag for some time, your doctor may tell you to stop taking eltrombopag.

Eltrombopag may help to control your condition but will not cure it. Continue to take eltrombopag even if you feel well. Do not stop taking eltrombopag without talking to your doctor.

What special precautions should I follow?

Before taking eltrombopag,

  • tell your doctor and pharmacist if you are allergic to eltrombopag, any other medications, or any of the ingredients in eltrombopag tablets. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: anticoagulants (blood thinners) such as warfarin (Coumadin, Jantoven); bosentan (Tracleer); cholesterol-lowering medications (statins) such as atorvastatin (Lipitor, in Caduet), fluvastatin (Lescol), pitavastatin (Livalo, Zypitamag), pravastatin (Pravachol), rosuvastatin (Crestor), and simvastatin (Zocor, Flolopid, in Vytorin); ezetimibe (Zetia, in Vytorin); glyburide (Diabeta, Glynase); imatinib (Gleevec); irinotecan (Camptosar, Onivyde); olmesartan (Benicar, in Azor, in Tribenzor); lapatinib (Tykerb); methotrexate (Rasuvo, Trexall, others); mitoxantrone; repaglinide (Prandin): rifampin (Rimactane, Rifadin, in Rifamate, Rifater); sulfasalazine (Azulfidine); topotecan (Hycamtin), and valsartan (Diovan, in Byvalson, in Entresto, in Exforge). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with eltrombopag, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
  • if you are taking antacids containing calcium, aluminum, or magnesium (Maalox, Mylanta, Tums) or vitamin or mineral supplements containing calcium, iron, zinc or selenium, take eltrombopag 2 hours before or 4 hours after you take them.
  • tell your doctor if you are of East Asian (Chinese, Japanese, Taiwanese, or Korean) descent and if you have or have ever had a cataract (clouding of the lens of the eye that may cause vision problems), blood clots, any condition that increases the risk that you will develop a blood clot, bleeding problems, myelodysplastic syndrome (MDS; a blood disorder that can lead to cancer), or liver disease. Also tell your doctor if you have had surgery to remove your spleen.
  • tell your doctor if you are pregnant, or plan to become pregnant. You should not become pregnant during your treatment with eltrombopag. Use effective birth control while you are receiving treatment and for 7 days after your last dose. If you become pregnant while taking eltrombopag, call your doctor.
  • tell your doctor if you are breastfeeding. You should not breastfeed while you are taking eltrombopag.
  • continue to avoid activities that may cause injury and bleeding during your treatment with eltrombopag. Eltrombopag is given to decrease the risk that you will experience severe bleeding, but there is still a risk that bleeding may occur.

References

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022291lbl.pdf
  2. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/promacta-eltrombopag-information
  3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207027s000lbl.pdf
  4. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022291s000_TOC.cfm
  5. https://pubchem.ncbi.nlm.nih.gov/compound/Eltrombopag
  6. https://pubchem.ncbi.nlm.nih.gov/compound/Eltrombopag-olamine
  7. https://go.drugbank.com/salts/DBSALT000063
  8. https://www.cancer.gov/about-cancer/treatment/drugs/eltrombopagolamine
  9. https://en.wikipedia.org/wiki/Eltrombopag
  10. https://medlineplus.gov/druginfo/meds/a609011.html
  11. https://go.drugbank.com/drugs/DB06210
  12. https://www.drugs.com/mtm/eltrombopag.html
  13. https://www.mayoclinic.org/drugs-supplements/eltrombopag-oral-route/side-effects/drg-20072443
  14. ChEBI
    Eltrombopag
    http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:85010
    ChEBI Ontology
    http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
  15. DrugBank
    https://www.drugbank.ca/legal/terms_of_use
    Eltrombopag
    https://www.drugbank.ca/drugs/DB06210
  16. FDA Pharm Classes
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    ELTROMBOPAG
    https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm
    FDA Pharmacological Classification
    https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
  17. NCI Thesaurus (NCIt)
    https://www.cancer.gov/policies/copyright-reuse
    https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C71634
    NCI Thesaurus Tree
    https://ncit.nci.nih.gov
  18. ChemIDplus
    LICENSE
    https://www.nlm.nih.gov/copyright.html
    Eltrombopag [INN]
    https://chem.nlm.nih.gov/chemidplus/sid/0496775612
    ChemIDplus Chemical Information Classification
    https://chem.nlm.nih.gov/chemidplus/
  19. EPA DSSTox
    LICENSE
    https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources
    Eltrombopag
    https://comptox.epa.gov/dashboard/DTXSID5057753
    CompTox Chemicals Dashboard Chemical Lists
    https://comptox.epa.gov/dashboard/chemical-lists/
  20. European Chemicals Agency (ECHA)
    https://echa.europa.eu/web/guest/legal-notice
    https://echa.europa.eu/substance-information/-/substanceinfo/100.128.125
    https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/108623
  21. FDA Global Substance Registration System (GSRS)
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    ELTROMBOPAG
    https://gsrs.ncats.nih.gov/ginas/app/beta/substances/S56D65XJ9G
  22. Hazardous Substances Data Bank (HSDB)
    Eltrombopag
    https://pubchem.ncbi.nlm.nih.gov/source/hsdb/8212
  23. ClinicalTrials.gov
    https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
    https://clinicaltrials.gov/
  24. Comparative Toxicogenomics Database (CTD)
    http://ctdbase.org/about/legal.jsp
    eltrombopag
    https://ctdbase.org/detail.go?type=chem&acc=C520809
    romiplostim
    https://ctdbase.org/detail.go?type=chem&acc=C488777
  25. Drug Gene Interaction database (DGIdb)
    http://www.dgidb.org/downloads
    ELTROMBOPAG
    https://www.dgidb.org/drugs/ELTROMBOPAG
  26. IUPHAR/BPS Guide to PHARMACOLOGY
    https://www.guidetopharmacology.org/about.jsp#license
    eltrombopag
    https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6961
    Guide to Pharmacology Target Classification
    https://www.guidetopharmacology.org/targets.jsp
  27. Therapeutic Target Database (TTD)
    Eltrombopag
    http://idrblab.net/ttd/data/drug/details/D00PEH
  28. European Medicines Agency (EMA)
    https://www.ema.europa.eu/en/about-us/legal-notice
    Revolade (EMEA/H/C/001110)
    https://www.ema.europa.eu/en/medicines/human/EPAR/revolade
    Eltrombopag (P/0070/2019)
    https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000170-pip02-10-m03
    Eltrombopag (P/0167/2016)
    https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000170-pip01-07-m04
    Eltrombopag (P/0516/2020)
    https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000170-pip03-13-m04
  29. EU Clinical Trials Register
    https://www.clinicaltrialsregister.eu/
  30. NORMAN Suspect List Exchange
    https://creativecommons.org/licenses/by/4.0/
    NORMAN Suspect List Exchange Classification
    https://www.norman-network.com/nds/SLE/
  31. WHO Anatomical Therapeutic Chemical (ATC) Classification
    https://www.whocc.no/copyright_disclaimer/
    https://www.whocc.no/atc/
    ATC Code
    https://www.whocc.no/atc_ddd_index/
  32. Human Metabolome Database (HMDB)
    http://www.hmdb.ca/citing
    Eltrombopag
    http://www.hmdb.ca/metabolites/HMDB0251758
  33. MassBank of North America (MoNA)
    https://mona.fiehnlab.ucdavis.edu/documentation/license
    Eltrombopag (SB-497115-GR)
    https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=
  34. NIPH Clinical Trials Search of Japan
    https://rctportal.niph.go.jp/en/
  35. NLM RxNorm Terminology
    https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
    eltrombopag
    https://rxnav.nlm.nih.gov/id/rxnorm/711942
  36. PubChem
    https://pubchem.ncbi.nlm.nih.gov
  37. Springer Nature
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=33056310-922399712
  38. Thieme Chemistry
    https://creativecommons.org/licenses/by-nc-nd/4.0/
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=33056329-439359869
  39. Wikidata
    https://creativecommons.org/publicdomain/zero/1.0/
    Eltrombopag
    https://www.wikidata.org/wiki/Q411588
  40. Medical Subject Headings (MeSH)
    https://www.nlm.nih.gov/copyright.html
    eltrombopag
    https://www.ncbi.nlm.nih.gov/mesh/67520809
    MeSH Tree
    http://www.nlm.nih.gov/mesh/meshhome.html
  41. UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)
    GHS Classification Tree
    http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
  42. ChEMBL
  43. http://www.ebi.ac.uk/Information/termsofuse.html
    ChEMBL Protein Target Tree
    https://www.ebi.ac.uk/chembl/g/#browse/targets
  44. PATENTSCOPE (WIPO)
    SID 461762755
    https://pubchem.ncbi.nlm.nih.gov/substance/461762755

RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Orthopedic / spine specialist, physical medicine doctor, or qualified clinician
Tests to discuss with doctor
  • Neurological examination for leg power, sensation, reflexes, and straight leg raise
  • X-ray only if injury, deformity, long-lasting pain, or doctor suspects bone problem
  • MRI discussion if severe nerve symptoms, weakness, bladder/bowel problem, or persistent symptoms
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Is physiotherapy, posture correction, or activity modification needed?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Eltrombopag Olamine – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of Action Eltrombopag is an orally bioavailable, small-molecule TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor. Eltrombopag is a stimulator of STAT and JAK phosphorylation. Unlike recombinant TPO or romiplostim, Eltrombopag does not activate the AKT pathway in any way. It should be noted that when given to patients with aplastic anemia, other lineages besides platelet count were increased, suggesting that either eltrombopag enhanced the effect of TPO in vivo; or there is a yet uncovered mechanism of action at work. Eltrombopag is an orally bioavailable, small-molecule thrombopoietin (TPO)-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor and initiates signaling cascades that induce proliferation and differentiation from bone marrow progenitor cells. Indications Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction. Eltrombopag is indicated for the treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e. g. corticosteroids, and immunoglobulins). Eltrombopagis indicated for the treatment of pediatric patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. g. corticosteroids, immunoglobulins). Eltrombopag is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy. Eltrombopag is indicated in adult patients with acquired severe aplastic anemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for hematopoietic stem cell transplantation Eltrombopag is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag is indicated for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Eltrombopag is indicated for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. Eltrombopag should be used only in patients with immune (idiopathic) thrombocytopenia (ITP) whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Promacta should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for the treatment of chronic hepatitis C infection.  In combination with standard immunosuppressive therapy as first-line treatment of patients with severe aplastic anemia. Use in Cancer. Eltrombopag olamine is approved to treat: Thrombocytopenia (low platelet levels). It is used in adults and in children aged 1 year or older with chronic immune thrombocytopenia (ITP). ITP is a condition in which platelets are destroyed by the immune system. Eltrombopag olamine is used in certain patients with ITP who have not gotten better with other treatments. Eltrombopag olamine is also being studied in the treatment of other conditions and types of cancer. Contraindications increase in the number of platelets in the blood clouding of the lens of the eye called cataracts obstruction of a blood vessel by a blood clot a blood clot in a vein of the liver at risk for formation of blood clots acute liver failure damage to the liver and inflammation decreased kidney function high amount of bilirubin in the blood abnormal liver function tests a patient who is producing milk and breastfeeding antiphospholipid antibody syndrome abnormal blood clotting due to factor V leiden mutation hereditary antithrombin III deficiency Child-Pugh class A liver impairment Child-Pugh class B liver impairment Child-Pugh class C liver impairment Dosage Strengths: 25 mg; 50 mg; 75 mg; 12.5 mg Aplastic Anemia FIRST-LINE SEVERE APLASTIC ANEMIA: Initial dose: 150 mg orally once a day Patients of Asian Ancestry (such as Chinese, Japanese, Taiwanese, Korean, or Thai): Initial dose: 75 mg orally once a day Duration of therapy: 6 months If baseline ALT or AST levels are greater than 6 times the upper limit of normal (ULN), do not initiate this drug until transaminase levels are less than 5 x ULN. Initiate this drug concurrently with standard immunosuppressive therapy. Do not exceed the initial dose. REFRACTORY SEVERE APLASTIC ANEMIA: Initial dose: 50 mg orally once a day; may adjust the dose in 50 mg increments every 2 weeks as needed to achieve a platelet count between 50 and 200 x 10(9)/L. Initial dose: 25 mg orally once a day; may adjust the dose in 50 mg increments every 2 weeks as needed to achieve a platelet count between 50 and 200 x 10(9)/L. Maintenance dose: The lowest dose needed to achieve and maintain a platelet count between 50 and 200 x 10(9)/L. Maximum dose: 150 mg orally once a day Duration of therapy: If no hematologic response has occurred after 16 weeks of therapy with this drug, discontinue therapy. For patients who achieve trilineage response, including transfusion independence, lasting at least 8 weeks, the dose of this drug may be reduced by 50%. If counts remain stable after 8 weeks at the reduced dose, then this drug may be discontinued. If platelet counts drop to less than 30 x 10(9)/L, hemoglobin to less than 9 g/dL, or absolute neutrophil count (ANC) to less than 0.5 x 10(9)/L, this drug may be reinitiated at the previous effective dose If new cytogenetic abnormalities are observed, consider discontinuation of this drug. Idiopathic (Immune) Thrombocytopenic Purpura Initial dose: 50 mg orally once a day Initial dose: 25 mg orally once a day Maintenance dose: The lowest dose to achieve and maintain a platelet count between 50 to 200 x 10(9)/L as necessary to reduce the risk of bleeding. Maximum dose: 75 mg orally once a day Duration: Treatment should be discontinued if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks of therapy at the maximum daily dose. Monitor CBC with differentials, including platelet counts, every week until the platelet count is stable, followed by monthly thereafter. Monitoring should continue every week for at least 4 weeks following treatment discontinuation. Platelet counts generally increase within 1 to 2 weeks after starting therapy and decrease within 1 to 2 weeks after treatment discontinuation. Thrombocytopenia Initial dose: 25 mg orally once a day Maintenance dose: The lowest dose to achieve and maintain a platelet count necessary to initiate and maintain antiviral therapy with pegylated interferon and ribavirin. Maximum dose: 100 mg orally once a day Duration: Treatment should be discontinued when concomitant antiviral therapy is discontinued Adjust the daily dose by increments of 25 mg every two weeks as necessary according to platelet count response. Monitor platelet counts every week prior to starting antiviral therapy. During antiviral therapy, monitor CBC with differentials, including platelet counts, every week until the platelet count is stable. Monitor platelet counts monthly thereafter. Platelet counts generally begin to rise within the first week of treatment with eltrombopag. Treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Pediatric Dose Idiopathic (Immune) Thrombocytopenic Purpura 1 TO 5 YEARS: Initial dose: 25 mg orally once a day 6 YEARS OR OLDER: Initial dose: 50 mg orally once a day Initial dose: 25 mg orally once a day Maintenance dose: The lowest dose to achieve and maintain a platelet count between 50 to 200 x 10(9)/L as necessary to reduce the risk of bleeding. Maximum dose: 75 mg orally once a day Duration: Treatment should be discontinued if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks of therapy at the maximum daily dose. Monitor CBC with differentials, including platelet counts, every week until the platelet count is stable, followed by monthly thereafter. Monitoring should continue every week for at least 4 weeks following treatment discontinuation. Platelet counts generally increase within 1 to 2 weeks after starting therapy and decrease within 1 to 2 weeks after treatment discontinuation. Aplastic Anemia FIRST-LINE SEVERE APLASTIC ANEMIA: Initial dose: 2 to 5 years: 2.5 mg/kg orally once a day 6 to 11 years: 75 mg orally once a day 12 years or older: 150 mg orally once a day Patients of Asian ancestry (such as Chinese, Japanese, Taiwanese, Korean, or Thai): Initial dose: 2 to 5 years: 1.25 mg/kg orally once a day 6 to 11 years: 37.5 mg orally once a day 12 years or older: 75 mg orally once a day Duration of therapy: 6 months If baseline ALT or AST levels are greater than 6 times the upper limit of normal (ULN), do not initiate this drug until transaminase levels are less than 5 x ULN. Initiate this drug concurrently with standard immunosuppressive therapy. Do not exceed the initial dose. Liver Dose Adjustments CHRONIC IMMUNE THROMBOCYTOPENIA: Mild to severe liver dysfunction (Child-Pugh A, B, or C): Initiate dose at 25 mg orally once a day Mild to severe liver dysfunction with East Asian ancestry: Initiate dose at 12.5 mg orally once a day In patients with liver dysfunction (Child-Pugh Class A, B, C), after initiating eltrombopag or after any subsequent dosing increase, wait 3 weeks before increasing the dose. CHRONIC HEPATITIS C-ASSOCIATED THROMBOCYTOPENIA: Liver dysfunction: No dosage adjustment is recommended FIRST-LINE SEVERE APLASTIC ANEMIA: If baseline ALT or AST levels are greater than 6 times the upper limit of normal (ULN), do not initiate this drug until transaminase levels are less than 5 x ULN. Mild to Severe Liver Dysfunction (Child-Pugh A, B, or C): Initial dose: 2 to 5 years: 1.25 mg/kg orally once a day for 6 months 6 to 11 years: 37.5 mg orally once a day for 6 months 12 years or older: 75 mg orally once a day for 6 months Increase in ALT or AST greater than 6 x ULN: Discontinue this drug. Once ALT or AST is less than 5 x ULN, reinitiate this drug at the same dose. Increase in ALT or AST greater than 6 x ULN after reinitiating this drug: Discontinue this drug and monitor ALT or AST at least every 3 to 4 days. Once ALT or AST is less than 5 x ULN, reinitiate this drug at a daily dose reduced by 25 mg compared to the previous dose. If ALT or AST returns to greater than 6 x ULN on the reduced dose: Reduce the daily dose of this drug by 25 mg until ALT or AST is less than 5 x ULN. In pediatric patients, less than 12 years of age, reduce the daily dose by at least 15% to the nearest dose that can be administered. REFRACTORY SEVERE APLASTIC ANEMIA: Mild to Severe Liver Dysfunction (Child-Pugh A, B, or C): Initial dose: 25 mg orally once a day GENERAL: Discontinue eltrombopag if ALT levels increase by at least 3 x ULN in patients with normal liver function or transaminases increase by at least 3 x baseline levels in patients with elevated transaminases pretreatment and where transaminases are: Progressively increasing, Persistent for at least 4 weeks, Accompanied by increased direct bilirubin, or Accompanied by clinical symptoms of liver injury or evidence of hepatic decompensation Treatment may be cautiously restarted if the benefits outweigh the risks, with weekly LFT monitoring during the dose adjustment phase; however, it should be permanently discontinued if LFT abnormalities remain, worsen, or reoccur. Dose Adjustments General: A period of at least 2 weeks is recommended between dose adjustments in order to see the effect on the platelet count. Excessive platelet count responses necessitate eltrombopag treatment discontinuation. Thrombocytopenia in Patients with Chronic ITP: General: Modify the dosage regimen of concomitant ITP medications, as medically appropriate, to avoid excessive increases in platelet counts during eltrombopag therapy. Platelet count: Less than 50 x 10(9)/L following at least 2 weeks of eltrombopag therapy: Increase daily dose by 25 mg to a maximum of 75 mg per day. For patients taking 12.5 mg once a day, increase the dose to 25 mg once a day before increasing the dose amount by 25 mg. Greater than or equal to 200 x 10(9)/L to less than or equal to 400 x 10(9)/L at any time: Decrease the daily dose by 25 mg. For patients taking 25 mg once a day, decrease the dose to 12.5 mg once a day. Greater than 400 x 10(9)/L: Stop eltrombopag; increase platelet monitoring to twice weekly. Once the platelet count is less than 150 x 10(9)/L, restart eltrombopag at a daily dose reduced by 25 mg. For patients taking 25 mg once a day, restart therapy at 12.5 mg once a day. Greater than 400 x 10(9)/L after 2 weeks of therapy at the lowest dose of eltrombopag: Discontinue eltrombopag Thrombocytopenia in Patients with Chronic Hepatitis C: General: During antiviral therapy, the dose of eltrombopag should be adjusted to avoid dose reductions of peginterferon. Eltrombopag should be discontinued when antiviral therapy is discontinued. Platelet count: Less than 50 x 10(9)/L following at least 2 weeks of eltrombopag therapy: Increase daily dose by 25 mg to a maximum of 100 mg per day Greater than or equal to 200 x 10(9)/L to less than or equal to 400 x 10(9)/L at any time: Decrease the daily dose by 25 mg Greater than 400 x 10(9)/L: Stop eltrombopag; increase platelet monitoring to twice weekly. Once the platelet count is less than 150 x 10(9)/L, restart eltrombopag at a daily dose reduced by 25 mg. For patients taking 25 mg once a day, restart therapy at 12.5 mg once a day. Greater than 400 x 10(9)/L after 2 weeks of therapy at the lowest dose of eltrombopag: Discontinue eltrombopag First-line Severe Aplastic Anemia: Platelet count: Greater than 200 x 10(9)/L to less than or equal to 400 x 10(9)/L: Decrease the daily dose by 25 mg every 2 weeks to the lowest dose that maintains a platelet count of at least 50 x 10(9)/L. In pediatric patients less than 12 years of age, decrease the dose by 12.5 mg. Greater than 400 x 10(9)/L: Discontinue this drug for 1 week. Once the platelet count is less than 200 x 10(9)/L, reinitiate this drug at a daily dose reduced by 25 mg (or 12.5 mg in pediatric patients less than 12 years of age). Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolus, stroke, myocardial infarction): Discontinue this drug but remain on horse anti-thymocyte globulin (h-ATG) and cyclosporine. Refractory Severe Aplastic Anemia: Platelet count: Less than 50 x 10(9)/L following at least 2 weeks of this drug: Increase daily dose by 50 mg to a maximum of 150 mg/day. For patients taking 25 mg once a day, increase the dose to 50 mg once a day before increasing the dose amount by 50 mg. Greater than or equal to 200 x 10(9)/L to less than or equal to 400 x 10(9)/L at any time: Decrease the daily dose by 50 mg. Greater than 400 x 10(9)/L: Stop this drug for 1 week. Once the platelet count is less than 150 x 10(9)/L, reinitiate therapy at a dose reduced by 50 mg. Greater than 400 x 10(9)/L after 2 weeks of therapy at the lowest dose of this drug: Discontinue this drug. Administration advice: This drug should be taken without a meal or with a meal low in calcium (50 mg or less) and at least 2 hours before or 4 hours after other medications (e.g., antacids), calcium-rich foods, or supplements containing polyvalent cations such as iron, calcium, aluminum, magnesium, selenium, and zinc. Do not administer more than one dose of eltrombopag within any 24-hour period. Do not split, chew, or crush tablets and mix them with food or liquids. Side Effects The Most Common back pain muscle aches or spasms headache flu symptoms such as fever, headache, sore throat, cough, tiredness, chills, and body aches weakness extreme tiredness decreased appetite pain or swelling in the mouth or throat hair loss rash skin color changes skin tingling, itching, or burning swelling of the ankles, feet, or lower legs toothache (in children) swelling, pain, tenderness, warmth or redness in one leg shortness of breath, coughing up blood, fast heartbeat, fast breathing, pain when breathing deeply pain in the chest, arms, back, neck, jaw, or stomach, breaking out in cold sweat, lightheadedness slow or difficult speech, sudden weakness or numbness of the face, arm or leg, sudden headache, sudden vision problems, sudden difficulty walking stomach pain, nausea, vomiting, diarrhea cloudy, blurry vision, or other vision changes More common Bloating or swelling of the face, arms, hands, lower legs, or feet body aches or pain chills cough difficulty with breathing fever headache loss of voice pain in the chest, groin, or legs, especially the calves pale skin rapid weight gain runny nose severe, sudden headache slurred speech sore throat sudden loss of coordination sudden, severe weakness or numbness in the arm or leg tingling of the hands or feet troubled breathing with exertion unusual tiredness or weakness unusual weight gain or loss yellow eyes or skin Decreased appetite difficulty with moving hair loss or thinning of the hair itching skin lack or loss of strength muscle cramps or stiffness swollen joints Rare Bladder pain blindness blurred or decreased vision bruising burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings diarrhea a general feeling of discomfort or illness hoarseness joint pain lower back or side pain muscle aches and pains nausea pinpoint red spots on the skin redness of the eye shivering sweating tender, swollen glands in the neck trouble sleeping trouble swallowing voice changes vomiting Back pain belching bone pain darkening of the skin dry mouth heartburn indigestion rash stomach discomfort, upset, or pain Drug Interactions DRUG INTERACTION Abacavir The metabolism of Abacavir can be decreased when combined with Eltrombopag. Abametapir The serum concentration of Eltrombopag can be increased when it is combined with Abametapir. Abatacept The metabolism of Eltrombopag can be increased when combined with Abatacept. Abemaciclib Eltrombopag may decrease the excretion rate of Abemaciclib which could result in a higher serum level. Abiraterone The serum concentration of Eltrombopag can be increased when it is combined with Abiraterone. Acemetacin The metabolism of Acemetacin can be decreased when combined with Eltrombopag. Acenocoumarol The metabolism of Eltrombopag can be decreased when combined with Acenocoumarol. Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Eltrombopag. Acetylsalicylic acid The metabolism of Acetylsalicylic acid can be decreased when combined with Eltrombopag. Acyclovir The metabolism of Eltrombopag can be decreased when combined with Acyclovir. Adalimumab The metabolism of Eltrombopag can be increased when combined with Adalimumab. Adenine The metabolism of Eltrombopag can be decreased when combined with Adenine. Afatinib Eltrombopag may decrease the excretion rate of Afatinib which could result in a higher serum level. Agomelatine The metabolism of Agomelatine can be decreased when combined with Eltrombopag. Albendazole The metabolism of Eltrombopag can be increased when combined with Albendazole. Allopurinol Eltrombopag may decrease the excretion rate of Allopurinol which could result in a higher serum level. Almotriptan The metabolism of Almotriptan can be decreased when combined with Eltrombopag. Alosetron The metabolism of Eltrombopag can be decreased when combined with Alosetron. Alpelisib The serum concentration of Alpelisib can be increased when it is combined with Eltrombopag. Aluminium Aluminium can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminium Aluminium phosphate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminum chloride Aluminum chloride can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminum oxide Aluminum oxide can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminum sulfate Aluminum sulfate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Ambrisentan The metabolism of Ambrisentan can be decreased when combined with Eltrombopag. Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Eltrombopag. Aminophylline The metabolism of Eltrombopag can be decreased when combined with Aminophylline. Amiodarone The metabolism of Amiodarone can be decreased when combined with Eltrombopag. Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Eltrombopag. Amodiaquine The metabolism of Amodiaquine can be decreased when combined with Eltrombopag. Anagrelide The metabolism of Eltrombopag can be decreased when combined with Anagrelide. Anakinra The metabolism of Eltrombopag can be increased when combined with Anakinra. Anastrozole The metabolism of Anastrozole can be decreased when combined with Eltrombopag. Antipyrine The metabolism of Antipyrine can be decreased when combined with Eltrombopag. Apalutamide The metabolism of Apalutamide can be decreased when combined with Eltrombopag. Apixaban The metabolism of Apixaban can be decreased when combined with Eltrombopag. Apomorphine The metabolism of Apomorphine can be decreased when combined with Eltrombopag. Apremilast The metabolism of Eltrombopag can be increased when combined with Apremilast. Armodafinil The metabolism of Eltrombopag can be increased when combined with Armodafinil. Artenimol The metabolism of Artenimol can be decreased when combined with Eltrombopag. Artesunate The metabolism of Artesunate can be decreased when combined with Eltrombopag. Asciminib The metabolism of Eltrombopag can be decreased when combined with Asciminib. Asenapine The metabolism of Asenapine can be decreased when combined with Eltrombopag. Asunaprevir The excretion of Asunaprevir can be decreased when combined with Eltrombopag. Atazanavir The metabolism of Eltrombopag can be decreased when combined with Atazanavir. Atogepant The serum concentration of Atogepant can be increased when it is combined with Eltrombopag. Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Eltrombopag. Avatrombopag The metabolism of Eltrombopag can be increased when combined with Avatrombopag. Axitinib The metabolism of Axitinib can be decreased when combined with Eltrombopag. Azathioprine The metabolism of Eltrombopag can be decreased when combined with Azathioprine. Azelastine The metabolism of Azelastine can be decreased when combined with Eltrombopag. Bazedoxifene The metabolism of Bazedoxifene can be decreased when combined with Eltrombopag. Belantamab mafodotin The excretion of Belantamab mafodotin can be decreased when combined with Eltrombopag. Belinostat The metabolism of Belinostat can be decreased when combined with Eltrombopag. Bempedoic acid The metabolism of Bempedoic acid can be decreased when combined with Eltrombopag. Bendamustine The metabolism of Bendamustine can be decreased when combined with Eltrombopag. Bentonite Bentonite can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Bentoquatam Bentoquatam can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Benzocaine The metabolism of Eltrombopag can be decreased when combined with Benzocaine. Benzyl alcohol The metabolism of Benzyl alcohol can be decreased when combined with Eltrombopag. Benzylpenicillin The excretion of Benzylpenicillin can be decreased when combined with Eltrombopag. Berotralstat The serum concentration of Berotralstat can be increased when it is combined with Eltrombopag. Betamethasone The metabolism of Eltrombopag can be increased when combined with Betamethasone. Betaxolol The metabolism of Eltrombopag can be decreased when combined with Betaxolol. Bexarotene The metabolism of Eltrombopag can be decreased when combined with Bexarotene. Bezafibrate The metabolism of Eltrombopag can be decreased when combined with Bezafibrate. Bictegravir The metabolism of Bictegravir can be decreased when combined with Eltrombopag. Bimekizumab The metabolism of Eltrombopag can be increased when combined with Bimekizumab. Binimetinib The metabolism of Binimetinib can be decreased when combined with Eltrombopag. Bortezomib The metabolism of Eltrombopag can be decreased when combined with Bortezomib. Bosentan The excretion of Bosentan can be decreased when combined with Eltrombopag. Bosutinib The metabolism of Eltrombopag can be decreased when combined with Bosutinib. Brigatinib The metabolism of Brigatinib can be decreased when combined with Eltrombopag. Brincidofovir The serum concentration of Brincidofovir can be increased when it is combined with Eltrombopag. Bromazepam The metabolism of Eltrombopag can be decreased when combined with Bromazepam. Bromotheophylline The metabolism of Bromotheophylline can be decreased when combined with Eltrombopag. Buprenorphine The metabolism of Buprenorphine can be decreased when combined with Eltrombopag. Cabazitaxel The metabolism of Cabazitaxel can be decreased when combined with Eltrombopag. Cabotegravir The metabolism of Cabotegravir can be decreased when combined with Eltrombopag. Cabozantinib The metabolism of Eltrombopag can be decreased when combined with Cabozantinib. Caffeine The metabolism of Eltrombopag can be decreased when combined with Caffeine. Calcium acetate The serum concentration of Eltrombopag can be decreased when it is combined with Calcium acetate. Calcium carbonate The serum concentration of Eltrombopag can be decreased when it is combined with Calcium carbonate. Calcium chloride The serum concentration of Eltrombopag can be decreased when it is combined with Calcium chloride. Calcium citrate The serum concentration of Eltrombopag can be decreased when it is combined with Calcium citrate. Calcium glucoh The serum concentration of Eltrombopag can be decreased when it is combined with Calcium glucoheptonate. Calcium gluconate The serum concentration of Eltrombopag can be decreased when it is combined with Calcium gluconate. Calcium lactate The serum concentration of Eltrombopag can be decreased when it is combined with Calcium lactate. Calcium Phosphate The serum concentration of Eltrombopag can be decreased when it is combined with Calcium Phosphate. Calcium polycarbophil The serum concentration of Eltrombopag can be decreased when it is combined with Calcium polycarbophil. Canagliflozin The metabolism of Canagliflozin can be decreased when combined with Eltrombopag. Canakinumab The metabolism of Eltrombopag can be increased when combined with Canakinumab. Candesartan cilexetil The metabolism of Eltrombopag can be decreased when combined with Candesartan cilexetil. Cannabidiol The metabolism of Eltrombopag can be decreased when combined with Cannabidiol. Capmatinib The metabolism of Eltrombopag can be decreased when combined with Capmatinib. Capsaicin The metabolism of Eltrombopag can be increased when combined with Capsaicin. Carbamazepine The metabolism of Eltrombopag can be increased when combined with Carbamazepine. Carmustine The metabolism of Eltrombopag can be decreased when combined with Carmustine. Carvedilol The metabolism of Carvedilol can be decreased when combined with Eltrombopag. Caspofungin The excretion of Caspofungin can be decreased when combined with Eltrombopag. Celecoxib The metabolism of Celecoxib can be decreased when combined with Eltrombopag. Cenobamate The metabolism of Eltrombopag can be increased when combined with Cenobamate. Cerivastatin The metabolism of Cerivastatin can be decreased when combined with Eltrombopag. Certolizumab pegol The metabolism of Eltrombopag can be increased when combined with Certolizumab pegol. Chloroquine The metabolism of Chloroquine can be decreased when combined with Eltrombopag. Chlorpromazine The metabolism of Eltrombopag can be decreased when combined with Chlorpromazine. Chlorzoxazone The metabolism of Eltrombopag can be decreased when combined with Chlorzoxazone. Cholecystokinin The excretion of Cholecystokinin can be decreased when combined with Eltrombopag. Cholic Acid The excretion of Cholic Acid can be decreased when combined with Eltrombopag. Cilostazol The metabolism of Eltrombopag can be decreased when combined with Cilostazol. Cimetidine The metabolism of Eltrombopag can be decreased when combined with Cimetidine. Cinacalcet The metabolism of Eltrombopag can be decreased when combined with Cinacalcet. Cinnarizine The metabolism of Eltrombopag can be decreased when combined with Cinnarizine. Cinoxacin The metabolism of Eltrombopag can be decreased when combined with Cinoxacin. Ciprofloxacin The metabolism of Eltrombopag can be decreased when combined with Ciprofloxacin. Cisapride The metabolism of Cisapride can be decreased when combined with Eltrombopag. Citalopram The metabolism of Eltrombopag can be decreased when combined with Citalopram. Cladribine Eltrombopag may decrease the excretion rate of Cladribine which could result in a higher serum level. Clofarabine Eltrombopag may decrease the excretion rate of Clofarabine which could result in a higher serum level. Clomipramine The metabolism of Eltrombopag can be decreased when combined with Clomipramine. Clonidine The metabolism of Eltrombopag can be decreased when combined with Clonidine. Clopidogrel The metabolism of Eltrombopag can be decreased when combined with Clopidogrel. Clozapine The metabolism of Eltrombopag can be decreased when combined with Clozapine. Codeine The metabolism of Codeine can be decreased when combined with Eltrombopag. Conjugated estrogens Eltrombopag may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level. Copanlisib Eltrombopag may decrease the excretion rate of Copanlisib which could result in a higher serum level. Curcumin The metabolism of Eltrombopag can be decreased when combined with Curcumin. Cyclobenzaprine The metabolism of Eltrombopag can be decreased when combined with Cyclobenzaprine. Cyclophosphamide The metabolism of Cyclophosphamide can be decreased when combined with Eltrombopag. Cyproheptadine The metabolism of Cyproheptadine can be decreased when combined with Eltrombopag. Cyproterone acetate The metabolism of Eltrombopag can be increased when combined with Cyproterone acetate. Dabigatran etexilate The metabolism of Dabigatran etexilate can be decreased when combined with Eltrombopag. Dabrafenib The serum concentration of Eltrombopag can be decreased when it is combined with Dabrafenib. Dacarbazine The metabolism of Eltrombopag can be decreased when combined with Dacarbazine. Dacomitinib Eltrombopag may decrease the excretion rate of Dacomitinib which could result in a higher serum level. Dactinomycin Eltrombopag may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Dapagliflozin The metabolism of Eltrombopag can be decreased when combined with Dapagliflozin. Dapsone The metabolism of Dapsone can be decreased when combined with Eltrombopag. Darolutamide Eltrombopag may decrease the excretion rate of Darolutamide which could result in a higher serum level. Dasabuvir The metabolism of Dasabuvir can be decreased when combined with Eltrombopag. Dasatinib Eltrombopag may decrease the excretion rate of Dasatinib which could result in a higher serum level. Daunorubicin Eltrombopag may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Deferasirox The serum concentration of Eltrombopag can be increased when it is combined with Deferasirox. Deferiprone The serum concentration of Deferiprone can be increased when it is combined with Eltrombopag. Delafloxacin Eltrombopag may decrease the excretion rate of Delafloxacin which could result in a higher serum level. Desogestrel The metabolism of Eltrombopag can be increased when combined with Desogestrel. Dexamethasone The metabolism of Eltrombopag can be increased when combined with Dexamethasone. Dexfenfluramine The metabolism of Eltrombopag can be decreased when combined with Dexfenfluramine. Dexibuprofen The metabolism of Dexibuprofen can be decreased when combined with Eltrombopag. Dexmedetomidine The metabolism of Eltrombopag can be decreased when combined with Dexmedetomidine. Dextromethorphan The metabolism of Dextromethorphan can be decreased when combined with Eltrombopag. Diacerein The metabolism of Eltrombopag can be decreased when combined with Diacerein. Diclofenac The metabolism of Diclofenac can be decreased when combined with Eltrombopag. Diethylstilbestrol The metabolism of Diethylstilbestrol can be decreased when combined with Eltrombopag. Digoxin The excretion of Digoxin can be decreased when combined with Eltrombopag. Dihydralazine The metabolism of Eltrombopag can be decreased when combined with Dihydralazine. Diltiazem The metabolism of Eltrombopag can be decreased when combined with Diltiazem. Dinoprostone The excretion of Dinoprostone can be decreased when combined with Eltrombopag. Disopyramide The metabolism of Eltrombopag can be decreased when combined with Disopyramide. Dolutegravir Eltrombopag may decrease the excretion rate of Dolutegravir which could result in a higher serum level. Domperidone The metabolism of Domperidone can be decreased when combined with Eltrombopag. Donepezil Eltrombopag may decrease the excretion rate of Donepezil which could result in a higher serum level. Dosulepin The metabolism of Eltrombopag can be decreased when combined with Dosulepin. Doxepin The metabolism of Eltrombopag can be decreased when combined with Doxepin. Doxorubicin Eltrombopag may decrease the excretion rate of Doxorubicin which could result in a higher serum level. Dronabinol The metabolism of Eltrombopag can be decreased when combined with Dronabinol. Duvelisib Eltrombopag may decrease the excretion rate of Duvelisib which could result in a higher serum level. Efavirenz The metabolism of Eltrombopag can be increased when combined with Efavirenz. Elagolix The metabolism of Elagolix can be decreased when combined with Eltrombopag. Eluxadoline The serum concentration of Eluxadoline can be increased when it is combined with Eltrombopag. Elvitegravir The metabolism of Elvitegravir can be decreased when combined with Eltrombopag. Emapalumab The metabolism of Eltrombopag can be increased when combined with Emapalumab. Enalapril The excretion of Enalapril can be decreased when combined with Eltrombopag. Enasidenib The metabolism of Enasidenib can be decreased when combined with Eltrombopag. Enoxacin The metabolism of Eltrombopag can be decreased when combined with Enoxacin. Entacapone The metabolism of Entacapone can be decreased when combined with Eltrombopag. Entecavir The metabolism of Eltrombopag can be decreased when combined with Entecavir. Enzalutamide The metabolism of Enzalutamide can be decreased when combined with Eltrombopag. Epirubicin The metabolism of Epirubicin can be decreased when combined with Eltrombopag. Erlotinib The metabolism of Erlotinib can be decreased when combined with Eltrombopag. Ertugliflozin Eltrombopag may decrease the excretion rate of Ertugliflozin which could result in a higher serum level. Erythromycin The excretion of Erythromycin can be decreased when combined with Eltrombopag. Eslicarbazepine The metabolism of Eslicarbazepine can be decreased when combined with Eltrombopag. Eslicarbazepine acetate The metabolism of Eslicarbazepine acetate can be decreased when combined with Eltrombopag. Estradiol The metabolism of Estradiol can be decreased when combined with Eltrombopag. Estradiol acetate The metabolism of Estradiol acetate can be decreased when combined with Eltrombopag. Estradiol benzoate The metabolism of Estradiol benzoate can be decreased when combined with Eltrombopag. Estradiol cypionate The metabolism of Estradiol cypionate can be decreased when combined with Eltrombopag. Estradiol dienanthate The metabolism of Estradiol dienanthate can be decreased when combined with Eltrombopag. Estradiol valerate The metabolism of Estradiol valerate can be decreased when combined with Eltrombopag. Estrone sulfate The metabolism of Eltrombopag can be decreased when combined with Estrone sulfate. Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Eltrombopag. Etanercept The metabolism of Eltrombopag can be increased when combined with Etanercept. Ethambutol The metabolism of Eltrombopag can be decreased when combined with Ethambutol. Ethanol The metabolism of Eltrombopag can be decreased when combined with Ethanol. Ethinylestradiol The metabolism of Eltrombopag can be increased when combined with Ethinylestradiol. Etodolac The metabolism of Etodolac can be decreased when combined with Eltrombopag. Etoposide The metabolism of Etoposide can be decreased when combined with Eltrombopag. Etoricoxib The metabolism of Eltrombopag can be decreased when combined with Etoricoxib. Ezetimibe Eltrombopag may decrease the excretion rate of Ezetimibe which could result in a higher serum level. Ezogabine The metabolism of Ezogabine can be decreased when combined with Eltrombopag. Famotidine The metabolism of Eltrombopag can be decreased when combined with Famotidine. Favipiravir The metabolism of Eltrombopag can be decreased when combined with Favipiravir. Febuxostat The metabolism of Febuxostat can be decreased when combined with Eltrombopag. Felodipine The metabolism of Eltrombopag can be decreased when combined with Felodipine. Fenfluramine The metabolism of Eltrombopag can be decreased when combined with Fenfluramine. Fenofibrate The metabolism of Fenofibrate can be decreased when combined with Eltrombopag. Ferric ammonium Ferric ammonium citrate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Ferric cation Ferric cation can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Ferric maltol Ferric maltol can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Ferric sulfate Ferric sulfate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Ferrous bisglycinate Ferrous bisglycinate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Ferrous fumarate Ferrous fumarate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Ferrous gluconate Ferrous gluconate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Ferrous succinate Ferrous succinate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Ferrous sulfate Ferrous sulfate anhydrous can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Ferumoxides Ferumoxides can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Ferumoxsil Ferumoxsil can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Fexinidazole The metabolism of Eltrombopag can be decreased when combined with Fexinidazole. Fexofenadine The excretion of Fexofenadine can be decreased when combined with Eltrombopag. Finerenone The metabolism of Finerenone can be decreased when combined with Eltrombopag. Flecainide The metabolism of Eltrombopag can be decreased when combined with Flecainide. Flunarizine The metabolism of Eltrombopag can be decreased when combined with Flunarizine. Flunitrazepam The metabolism of Eltrombopag can be decreased when combined with Flunitrazepam. Fluorouracil The metabolism of Fluorouracil can be decreased when combined with Eltrombopag. Fluoxetine The metabolism of Eltrombopag can be decreased when combined with Fluoxetine. Flurbiprofen The metabolism of Eltrombopag can be decreased when combined with Flurbiprofen. Flutamide The metabolism of Eltrombopag can be decreased when combined with Flutamide. Fluticasone The metabolism of Eltrombopag can be decreased when combined with Fluticasone. Fluticasone furoate The metabolism of Eltrombopag can be decreased when combined with Fluticasone furoate. Fluticasone propionate The metabolism of Eltrombopag can be decreased when combined with Fluticasone propionate. Fluvastatin The metabolism of Eltrombopag can be decreased when combined with Fluvastatin. Fluvoxamine The metabolism of Eltrombopag can be decreased when combined with Fluvoxamine. Folic acid Eltrombopag may decrease the excretion rate of Folic acid which could result in a higher serum level. Formoterol The metabolism of Formoterol can be decreased when combined with Eltrombopag. Fosphenytoin The metabolism of Fosphenytoin can be decreased when combined with Eltrombopag. Fostamatinib The metabolism of Eltrombopag can be decreased when combined with Fostamatinib. Fostemsavir Eltrombopag may decrease the excretion rate of Fostemsavir which could result in a higher serum level. Frovatriptan The metabolism of Eltrombopag can be decreased when combined with Frovatriptan. Fulvestrant The metabolism of Fulvestrant can be decreased when combined with Eltrombopag. Furosemide The metabolism of Furosemide can be decreased when combined with Eltrombopag. Fusidic acid The metabolism of Fusidic acid can be decreased when combined with Eltrombopag. Gadoxetic acid The excretion of Gadoxetic acid can be decreased when combined with Eltrombopag. Gatifloxacin The metabolism of Eltrombopag can be decreased when combined with Gatifloxacin. Gefitinib Eltrombopag may decrease the excretion rate of Gefitinib which could result in a higher serum level. Gemfibrozil The metabolism of Eltrombopag can be decreased when combined with Gemfibrozil. Gemifloxacin The metabolism of Eltrombopag can be decreased when combined with Gemifloxacin. Givosiran The serum concentration of Eltrombopag can be increased when it is combined with Givosiran. Glasdegib The metabolism of Glasdegib can be decreased when combined with Eltrombopag. Glecaprevir Eltrombopag may decrease the excretion rate of Glecaprevir which could result in a higher serum level. Glipizide The metabolism of Glipizide can be decreased when combined with Eltrombopag. Glyburide Eltrombopag may decrease the excretion rate of Glyburide which could result in a higher serum level. Golimumab The metabolism of Eltrombopag can be increased when combined with Golimumab. Grazoprevir The excretion of Grazoprevir can be decreased when combined with Eltrombopag. Grepafloxacin The metabolism of Eltrombopag can be decreased when combined with Grepafloxacin. Guanabenz The metabolism of Eltrombopag can be decreased when combined with Guanabenz. Halofantrine The metabolism of Halofantrine can be decreased when combined with Eltrombopag. Haloperidol The metabolism of Eltrombopag can be decreased when combined with Haloperidol. Hydrocortisone The metabolism of Eltrombopag can be increased when combined with Hydrocortisone. Hydromorphone The metabolism of Hydromorphone can be decreased when combined with Eltrombopag. Hydrotalcite Hydrotalcite can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Hydroxychloroquine The metabolism of Hydroxychloroquine can be decreased when combined with Eltrombopag. Ibuprofen The metabolism of Ibuprofen can be decreased when combined with Eltrombopag. Idelalisib Eltrombopag may decrease the excretion rate of Idelalisib which could result in a higher serum level. Ifosfamide The metabolism of Ifosfamide can be decreased when combined with Eltrombopag. Imatinib The metabolism of Imatinib can be decreased when combined with Eltrombopag. Imipramine The metabolism of Eltrombopag can be decreased when combined with Imipramine. Indacaterol The metabolism of Indacaterol can be decreased when combined with Eltrombopag. Indinavir The metabolism of Eltrombopag can be decreased when combined with Indinavir. Indomethacin The metabolism of Eltrombopag can be decreased when combined with Indomethacin. Infliximab The metabolism of Eltrombopag can be increased when combined with Infliximab. Insulin beef The metabolism of Eltrombopag can be increased when combined with Insulin beef. Insulin pork The metabolism of Eltrombopag can be increased when combined with Insulin pork. Interferon alfa-2a The metabolism of Eltrombopag can be decreased when combined with Interferon alfa-2a. Interferon alfa-2b The metabolism of Eltrombopag can be decreased when combined with Interferon alfa-2b. Interferon alfa-n1 The metabolism of Eltrombopag can be decreased when combined with Interferon alfa-n1. Interferon alfa-n3 The metabolism of Eltrombopag can be decreased when combined with Interferon alfa-n3. Interferon alfacon-1 The metabolism of Eltrombopag can be decreased when combined with Interferon alfacon-1. Interferon beta-1a The metabolism of Eltrombopag can be decreased when combined with Interferon beta-1a. Interferon beta-1b The metabolism of Eltrombopag can be decreased when combined with Interferon beta-1b. Interferon gamma-1b The metabolism of Eltrombopag can be decreased when combined with Interferon gamma-1b. Irbesartan The metabolism of Eltrombopag can be decreased when combined with Irbesartan. Irinotecan The risk or severity of neutropenia can be increased when Eltrombopag is combined with Irinotecan. Iron Iron can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Iron Dextran Iron Dextran can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Iron sucrose Iron sucrose can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Isavuconazole The metabolism of Eltrombopag can be decreased when combined with Isavuconazole. Isoniazid The metabolism of Eltrombopag can be decreased when combined with Isoniazid. Istradefylline The metabolism of Istradefylline can be decreased when combined with Eltrombopag. Ivermectin Eltrombopag may decrease the excretion rate of Ivermectin which could result in a higher serum level. Kaolin Kaolin can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Ketamine The metabolism of Ketamine can be decreased when combined with Eltrombopag. Ketoconazole The metabolism of Eltrombopag can be decreased when combined with Ketoconazole. Ketoprofen The metabolism of Ketoprofen can be decreased when combined with Eltrombopag. Ketorolac The metabolism of Ketorolac can be decreased when combined with Eltrombopag. Labetalol The metabolism of Labetalol can be decreased when combined with Eltrombopag. Lamivudine Eltrombopag may decrease the excretion rate of Lamivudine which could result in a higher serum level. Lamotrigine The metabolism of Eltrombopag can be increased when combined with Lamotrigine. Lansoprazole The metabolism of Lansoprazole can be decreased when combined with Eltrombopag. Lapatinib The metabolism of Lapatinib can be decreased when combined with Eltrombopag. Leflunomide The serum concentration of Eltrombopag can be decreased when it is combined with Leflunomide. Lenvatinib Eltrombopag may decrease the excretion rate of Lenvatinib which could result in a higher serum level. Letermovir The metabolism of Letermovir can be decreased when combined with Eltrombopag. Levobupivacaine The metabolism of Eltrombopag can be decreased when combined with Levobupivacaine. Levoketoconazole The metabolism of Eltrombopag can be decreased when combined with Levoketoconazole. Levomilnacipran The metabolism of Levomilnacipran can be decreased when combined with Eltrombopag. Levosalbutamol The excretion of Levosalbutamol can be decreased when combined with Eltrombopag. Levothyroxine The metabolism of Levothyroxine can be decreased when combined with Eltrombopag. Lidocaine The metabolism of Eltrombopag can be decreased when combined with Lidocaine. Linzagolix The serum concentration of Eltrombopag can be increased when it is combined with Linzagolix. Liothyronine The metabolism of Liothyronine can be decreased when combined with Eltrombopag. Liotrix The metabolism of Eltrombopag can be decreased when combined with Liotrix. Lofexidine The metabolism of Eltrombopag can be decreased when combined with Lofexidine. Lomefloxacin The metabolism of Eltrombopag can be decreased when combined with Lomefloxacin. Lonapegsomatropin The metabolism of Eltrombopag can be increased when combined with Lonapegsomatropin. Loperamide The metabolism of Loperamide can be decreased when combined with Eltrombopag. Loratadine The metabolism of Eltrombopag can be decreased when combined with Loratadine. Lorcaserin The metabolism of Eltrombopag can be decreased when combined with Lorcaserin. Lorlatinib The metabolism of Lorlatinib can be decreased when combined with Eltrombopag. Losartan The metabolism of Losartan can be decreased when combined with Eltrombopag. Lovastatin The metabolism of Eltrombopag can be decreased when combined with Lovastatin. Lumacaftor The metabolism of Eltrombopag can be decreased when combined with Lumacaftor. Lumateperone The serum concentration of Lumateperone can be increased when it is combined with Eltrombopag. Lumiracoxib The metabolism of Lumiracoxib can be decreased when combined with Eltrombopag. Lusutrombopag Eltrombopag may decrease the excretion rate of Lusutrombopag which could result in a higher serum level. Magaldrate Magaldrate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium Magnesium can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium carbonate Magnesium carbonate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium chloride Magnesium chloride can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium citrate Magnesium citrate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium gluconate Magnesium gluconate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium hydroxide Magnesium hydroxide can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium oxide Magnesium oxide can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium silicate Magnesium silicate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium sulfate Magnesium sulfate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium trisilicate Magnesium trisilicate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Maprotiline The metabolism of Eltrombopag can be decreased when combined with Maprotiline. Medroxyprogesterone The metabolism of Eltrombopag can be decreased when combined with Medroxyprogesterone acetate. Mefenamic acid The metabolism of Eltrombopag can be decreased when combined with Mefenamic acid. Melatonin The metabolism of Eltrombopag can be decreased when combined with Melatonin. Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Eltrombopag. Mestranol The metabolism of Mestranol can be decreased when combined with Eltrombopag. Methimazole The metabolism of Eltrombopag can be decreased when combined with Methimazole. Methotrexate Eltrombopag may decrease the excretion rate of Methotrexate which could result in a higher serum level. Methoxsalen The metabolism of Eltrombopag can be decreased when combined with Methoxsalen. Methylene blue The metabolism of Eltrombopag can be decreased when combined with Methylene blue. Metoclopramide The metabolism of Eltrombopag can be decreased when combined with Metoclopramide. Metronidazole The metabolism of Metronidazole can be decreased when combined with Eltrombopag. Mexiletine The metabolism of Eltrombopag can be decreased when combined with Mexiletine. Mianserin The metabolism of Eltrombopag can be decreased when combined with Mianserin. Miconazole The metabolism of Eltrombopag can be decreased when combined with Miconazole. Midazolam The metabolism of Midazolam can be decreased when combined with Eltrombopag. Mifepristone The serum concentration of Eltrombopag can be increased when it is combined with Mifepristone. Migalastat The metabolism of Migalastat can be decreased when combined with Eltrombopag. Minoxidil The metabolism of Minoxidil can be decreased when combined with Eltrombopag. Mirtazapine The metabolism of Eltrombopag can be decreased when combined with Mirtazapine. Mitapivat The metabolism of Eltrombopag can be increased when combined with Mitapivat. Mitoxantrone Eltrombopag may decrease the excretion rate of Mitoxantrone which could result in a higher serum level. Mometasone furoate The metabolism of Eltrombopag can be decreased when combined with Mometasone furoate. Montelukast The metabolism of Montelukast can be decreased when combined with Eltrombopag. Morphine The metabolism of Morphine can be decreased when combined with Eltrombopag. Moxifloxacin The metabolism of Eltrombopag can be decreased when combined with Moxifloxacin. Mycophenolate mofetil The metabolism of Mycophenolate mofetil can be decreased when combined with Eltrombopag. Mycophenolic acid The metabolism of Mycophenolic acid can be decreased when combined with Eltrombopag. Nabumetone The metabolism of Eltrombopag can be decreased when combined with Nabumetone. Nafcillin The metabolism of Eltrombopag can be increased when combined with Nafcillin. Naldemedine The metabolism of Naldemedine can be decreased when combined with Eltrombopag. Nalidixic acid The metabolism of Eltrombopag can be decreased when combined with Nalidixic acid. Nalmefene The metabolism of Nalmefene can be decreased when combined with Eltrombopag. Naloxone The metabolism of Naloxone can be decreased when combined with Eltrombopag. Naltrexone The metabolism of Naltrexone can be decreased when combined with Eltrombopag. Naproxen The metabolism of Naproxen can be decreased when combined with Eltrombopag. Nateglinide The metabolism of Nateglinide can be decreased when combined with Eltrombopag. Nelfinavir The metabolism of Eltrombopag can be increased when combined with Nelfinavir. Nevirapine The metabolism of Eltrombopag can be decreased when combined with Nevirapine. Nicardipine The metabolism of Eltrombopag can be decreased when combined with Nicardipine. Niclosamide The metabolism of Eltrombopag can be decreased when combined with Niclosamide. Nifedipine The metabolism of Eltrombopag can be decreased when combined with Nifedipine. Nilotinib Eltrombopag may decrease the excretion rate of Nilotinib which could result in a higher serum level. Nilutamide The metabolism of Eltrombopag can be decreased when combined with Nilutamide. Nilvadipine The metabolism of Eltrombopag can be decreased when combined with Nilvadipine. Nintedanib The metabolism of Nintedanib can be decreased when combined with Eltrombopag. Nitrofurantoin Eltrombopag may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. Norfloxacin The metabolism of Eltrombopag can be decreased when combined with Norfloxacin. Norgestimate The metabolism of Norgestimate can be decreased when combined with Eltrombopag. Obeticholic acid The metabolism of Eltrombopag can be decreased when combined with Obeticholic acid. Olanzapine The metabolism of Eltrombopag can be decreased when combined with Olanzapine. Olodaterol The metabolism of Olodaterol can be decreased when combined with Eltrombopag. Ombitasvir The metabolism of Ombitasvir can be decreased when combined with Eltrombopag. Omeprazole The metabolism of Omeprazole can be decreased when combined with Eltrombopag. Ondansetron The metabolism of Eltrombopag can be decreased when combined with Ondansetron. Orphenadrine The metabolism of Eltrombopag can be decreased when combined with Orphenadrine. Osilodrostat The metabolism of Eltrombopag can be decreased when combined with Osilodrostat. Osimertinib The serum concentration of Eltrombopag can be decreased when it is combined with Osimertinib. Ouabain The excretion of Ouabain can be decreased when combined with Eltrombopag. Oxaliplatin Eltrombopag may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Oxazepam The metabolism of Oxazepam can be decreased when combined with Eltrombopag. Oxtriphylline The metabolism of Eltrombopag can be decreased when combined with Oxtriphylline. Oxybutynin The metabolism of Eltrombopag can be decreased when combined with Oxybutynin. Ozanimod Eltrombopag may decrease the excretion rate of Ozanimod which could result in a higher serum level. Paclitaxel The metabolism of Paclitaxel can be decreased when combined with Eltrombopag. Pacritinib The metabolism of Eltrombopag can be decreased when combined with Pacritinib. Palbociclib Eltrombopag may decrease the excretion rate of Palbociclib which could result in a higher serum level. Paramethadione The metabolism of Paramethadione can be decreased when combined with Eltrombopag. Paricalcitol The metabolism of Paricalcitol can be decreased when combined with Eltrombopag. Paritaprevir The metabolism of Eltrombopag can be decreased when combined with Paritaprevir. Paroxetine The metabolism of Eltrombopag can be decreased when combined with Paroxetine. Pazopanib The metabolism of Pazopanib can be decreased when combined with Eltrombopag. Pefloxacin The metabolism of Eltrombopag can be decreased when combined with Pefloxacin. Peginterferon alfa-2a The metabolism of Eltrombopag can be decreased when combined with Peginterferon alfa-2a. Peginterferon alfa-2b The serum concentration of Eltrombopag can be increased when it is combined with Peginterferon alfa-2b. Pemetrexed The metabolism of Eltrombopag can be decreased when combined with Pemetrexed. Penciclovir The metabolism of Eltrombopag can be decreased when combined with Penciclovir. Penicillamine The excretion of Penicillamine can be decreased when combined with Eltrombopag. Pentoxifylline The metabolism of Eltrombopag can be decreased when combined with Pentoxifylline. Perampanel The metabolism of Perampanel can be decreased when combined with Eltrombopag. Perflubutane Perflubutane can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Perphenazine The metabolism of Eltrombopag can be decreased when combined with Perphenazine. Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Eltrombopag. Phenobarbital The metabolism of Eltrombopag can be increased when combined with Phenobarbital. Phenprocoumon The metabolism of Phenprocoumon can be decreased when combined with Eltrombopag. Phenylephrine The metabolism of Eltrombopag can be increased when combined with Phenylephrine. Phenytoin The metabolism of Phenytoin can be decreased when combined with Eltrombopag. Pibrentasvir Eltrombopag may decrease the excretion rate of Pibrentasvir which could result in a higher serum level. Pimozide The metabolism of Eltrombopag can be decreased when combined with Pimozide. Pioglitazone The metabolism of Eltrombopag can be decreased when combined with Pioglitazone. Pirfenidone The metabolism of Eltrombopag can be decreased when combined with Pirfenidone. Piroxicam The metabolism of Piroxicam can be decreased when combined with Eltrombopag. Pitavastatin The metabolism of Pitavastatin can be decreased when combined with Eltrombopag. Pitolisant The metabolism of Eltrombopag can be increased when combined with Pitolisant. Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Eltrombopag. Ponatinib The metabolism of Ponatinib can be decreased when combined with Eltrombopag. Ponesimod The metabolism of Ponesimod can be decreased when combined with Eltrombopag. Potassium alum Potassium alum can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Pralatrexate Eltrombopag may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pralsetinib Eltrombopag may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Pravastatin Eltrombopag may decrease the excretion rate of Pravastatin which could result in a higher serum level. Praziquantel The metabolism of Eltrombopag can be decreased when combined with Praziquantel. Prazosin Eltrombopag may decrease the excretion rate of Prazosin which could result in a higher serum level. Prednisolone phosphate The metabolism of Eltrombopag can be increased when combined with Prednisolone phosphate. Primaquine The metabolism of Eltrombopag can be increased when combined with Primaquine. Primidone The metabolism of Eltrombopag can be increased when combined with Primidone. Probenecid The metabolism of Eltrombopag can be decreased when combined with Probenecid. Promazine The metabolism of Eltrombopag can be decreased when combined with Promazine. Propafenone The metabolism of Eltrombopag can be decreased when combined with Propafenone. Propofol The metabolism of Propofol can be decreased when combined with Eltrombopag. Propranolol The metabolism of Eltrombopag can be decreased when combined with Propranolol. Prussian blue Prussian blue can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Pyrimethamine The metabolism of Eltrombopag can be decreased when combined with Pyrimethamine. Quinidine The metabolism of Eltrombopag can be decreased when combined with Quinidine. Quinine The metabolism of Eltrombopag can be decreased when combined with Quinine. Raloxifene Eltrombopag may decrease the excretion rate of Raloxifene which could result in a higher serum level. Raltegravir The metabolism of Raltegravir can be decreased when combined with Eltrombopag. Ramelteon The metabolism of Eltrombopag can be decreased when combined with Ramelteon. Ranitidine The metabolism of Eltrombopag can be decreased when combined with Ranitidine. Rasagiline The metabolism of Eltrombopag can be decreased when combined with Rasagiline. Regorafenib The metabolism of Regorafenib can be decreased when combined with Eltrombopag. Repaglinide The metabolism of Repaglinide can be decreased when combined with Eltrombopag. Revefenacin Eltrombopag may decrease the excretion rate of Revefenacin which could result in a higher serum level. Rifabutin The metabolism of Eltrombopag can be increased when combined with Rifabutin. Rifampicin The metabolism of Eltrombopag can be increased when combined with Rifampicin. Rifamycin The metabolism of Eltrombopag can be decreased when combined with Rifamycin. Rifapentine The metabolism of Eltrombopag can be increased when combined with Rifapentine. Rilonacept The metabolism of Eltrombopag can be increased when combined with Rilonacept. Rilpivirine The metabolism of Eltrombopag can be decreased when combined with Rilpivirine. Riluzole Eltrombopag may decrease the excretion rate of Riluzole which could result in a higher serum level. Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Eltrombopag. Riociguat The metabolism of Riociguat can be decreased when combined with Eltrombopag. Ripretinib Eltrombopag may decrease the excretion rate of Ripretinib which could result in a higher serum level. Ritonavir The metabolism of Eltrombopag can be decreased when combined with Ritonavir. Rivaroxaban Eltrombopag may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. Rofecoxib The metabolism of Eltrombopag can be decreased when combined with Rofecoxib. Roflumilast The metabolism of Eltrombopag can be decreased when combined with Roflumilast. Ropeginterferon The metabolism of Eltrombopag can be decreased when combined with Ropeginterferon alfa-2b. Ropivacaine The metabolism of Eltrombopag can be decreased when combined with Ropivacaine. Rosiglitazone The metabolism of Rosiglitazone can be decreased when combined with Eltrombopag. Rosoxacin The metabolism of Eltrombopag can be decreased when combined with Rosoxacin. Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Eltrombopag. Roxadustat The metabolism of Roxadustat can be decreased when combined with Eltrombopag. Rucaparib Eltrombopag may decrease the excretion rate of Rucaparib which could result in a higher serum level. Sacituzumab govitecan The serum concentration of Sacituzumab govitecan can be increased when it is combined with Eltrombopag. Salmeterol The metabolism of Eltrombopag can be decreased when combined with Salmeterol. Saquinavir The metabolism of Eltrombopag can be decreased when combined with Saquinavir. Satralizumab The serum concentration of Eltrombopag can be decreased when it is combined with Satralizumab. Secobarbital The metabolism of Eltrombopag can be increased when combined with Secobarbital. Secukinumab The metabolism of Eltrombopag can be increased when combined with Secukinumab. Selegiline The metabolism of Selegiline can be decreased when combined with Eltrombopag. Selenic acid The bioavailability of Selenic acid can be decreased when combined with Eltrombopag. Selenious acid The bioavailability of Selenious acid can be decreased when combined with Eltrombopag. Selenium The bioavailability of Selenium can be decreased when combined with Eltrombopag. Selenomethionine The bioavailability of Selenomethionine can be decreased when combined with Eltrombopag. Selenomethionine The bioavailability of Selenomethionine Se-75 can be decreased when combined with Eltrombopag. Selexipag The metabolism of Selexipag can be decreased when combined with Eltrombopag. Selpercatinib The serum concentration of Eltrombopag can be increased when it is combined with Selpercatinib. Selumetinib The metabolism of Selumetinib can be decreased when combined with Eltrombopag. Silodosin The metabolism of Silodosin can be decreased when combined with Eltrombopag. Siltuximab The metabolism of Eltrombopag can be increased when combined with Siltuximab. Simeprevir The metabolism of Eltrombopag can be decreased when combined with Simeprevir. Simvastatin The metabolism of Simvastatin can be decreased when combined with Eltrombopag. Pregnancy and Lactation FDA Pregnancy Category C Pregnancy There are no adequate and well-controlled studies of eltrombopag use in pregnancy. In animal reproduction and developmental toxicity studies, there was evidence of embryolethality and reduced fetal weights at maternally toxic doses. PROMACTA should be us Lactation It is not known whether eltrombopag is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from PROMACTA, a decision should be made whether to discontinue nursing or to discontinue PROMACTA taking into account the importance of PROMACTA to the mother and the known benefits of nursing. How should this medicine be used?

Eltrombopag comes as a tablet and as a powder for oral suspension (liquid) to take by mouth. It is usually taken once a day on an empty stomach, at least 1 hour before or 2 hours after eating. Take eltrombopag at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take eltrombopag exactly as directed. Do not take more or less…

Continue exploring

Explore this topic across the RX Medical Library

Open a focused A–Z pathway or continue with closely related indexed articles. These links are educational and do not replace personal medical care.

Search this topic
Diseases A–Z Drugs A–Z Lab Tests A–Z Cancer A–Z
Diseases A–Z

Foodborne Illness (also foodborne disease and colloquially referred to as food poisoning)[rx] is any illness resulting from the spoilage of contaminated food, pathogenic bacteria, viruses, or parasites that…

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)